Filterlex Medical Completes Funding Round for Its Captis Clinical Program

November 18, 2021—Filterlex Medical Ltd., a cardiovascular medical device startup company based in Israel, announced that it has recently completed a $6 million Series A1 investment round from leading private health care investors.

According to Filterlex, the financing will accelerate implementation of the company’s Captis clinical program. Captis is a next-generation, full-body embolic protection device intended to reduce the risk of stroke and other complications during left-heart procedures, such as transcatheter aortic valve replacement (TAVR).

The company reported that the CAPTIS first-in-human study is ongoing and actively enrolling patients at two leading centers in Israel, Wolfson Medical Center in Holon, Israel, and Rabin Medical Center (Beilinson Hospital) in Petah Tikva, Israel. The study received funding through grant from the European Union’s Horizon 2020 research and innovation program.

Professor Haim Danenberg, MD, Head of Interventional Cardiology at the Wolfson Medical Center, is the study’s Principal Investigator.

Prof. Danenberg commented in the company’s press release, “We are thrilled with the opportunity to use the Captis device to protect our TAVR patients’ brain and kidneys.”

Professor Ran Kornowski, MD, who is Director of the Cardiology Center at Rabin Medical Center, added, “Our initial experience with the Captis is very positive. The system is safe, intuitive, and easy to use.”